Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival
2019 Quality Care SymposiumBernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive non–small cell lung cancer (Abstract 3).
Related Videos
Linda D. Bosserman, MD, on Pathways for Personalized Precision Medicine and Value
Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidan...
Karen M. Winkfield, MD, PhD, on Policy and Business Solutions to Address Disparities in Cancer Care
Karen M. Winkfield, MD, PhD, of the Wake Forest Baptist Medical Center, discusses cultural factors that contribute to cancer care disparities, the role of national policy in ...
Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial
Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her in...
Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists
Nadine Housri, MD, of the Yale School of Medicine, talks about a new paradigm in sharing knowledge from tumor board discussions at NCI-designated comprehensive cancer centers...
Manali I. Patel, MD, on Community Practices: Enhancing Delivery of Value-Based Cancer Care
Manali I. Patel, MD, of Stanford Cancer Center, discusses enhancing value for patients with cancer treated by community practitioners at the end of life by also utilizing tra...
